Mycoplasma Respiratory Infection

Mycoplasma respiratory infection is a chronic and often persistent respiratory disease in birds caused by various species of Mycoplasma, which are the smallest self-replicating bacteria known. These unique organisms lack a cell wall, which distinguishes them from typical bacteria and has implications for both their biology and treatment. Mycoplasma infections of the respiratory tract can affect both the upper and lower respiratory system, causing sinusitis, tracheitis, pneumonia, and air sacculitis. The infection is common in domestic poultry, game birds, and various pet bird species, though certain Mycoplasma species show preferences for particular host groups. Mycoplasmosis represents an important cause of chronic respiratory disease in avian populations and can be challenging to fully eradicate once established.

The Mycoplasma organisms that affect birds include several species with different host ranges and clinical presentations. Mycoplasma gallisepticum is one of the most important avian pathogens, primarily affecting chickens and turkeys but also causing disease in pet birds, particularly finches where it causes a distinctive conjunctivitis. Mycoplasma synoviae affects poultry and can spread to other species. Various Mycoplasma species have been isolated from psittacine birds with respiratory disease, though their role as primary pathogens versus secondary invaders is sometimes debated. Transmission occurs through direct contact with infected birds, aerosol transmission of respiratory secretions, and vertical transmission from infected parents to offspring through eggs.

The impact of mycoplasma respiratory infection on bird health varies from subclinical carrier states to significant chronic disease. Birds may carry Mycoplasma organisms without showing obvious signs, shedding bacteria and infecting other birds while appearing healthy. When clinical disease develops, it typically manifests as chronic respiratory signs including nasal discharge, sneezing, and respiratory sounds that may persist for weeks to months. The infection often causes swelling of sinuses, which is particularly visible around the eyes and infraorbital area. Secondary bacterial infections frequently complicate mycoplasma infection, worsening clinical signs. The chronic nature of the disease can lead to reduced quality of life, poor growth in young birds, and decreased production in breeding situations.

Mycoplasma respiratory infection is treatable with appropriate antibiotics, though treatment can be challenging and recurrence is common. Because Mycoplasma organisms lack a cell wall, antibiotics that target cell wall synthesis such as penicillins are ineffective. Effective antibiotics include tetracyclines, fluoroquinolones, and macrolides. Treatment must be continued for extended periods to suppress infection, and complete elimination of the organism may not be achieved. Prevention through biosecurity measures and testing is important for protecting collections and breeding programs. Any bird with chronic respiratory disease, particularly those with sinus involvement, should be evaluated for Mycoplasma infection as part of a comprehensive diagnostic workup.

The primary cause of mycoplasma respiratory infection is infection with one or more species of Mycoplasma bacteria. These organisms are uniquely adapted for survival on mucosal surfaces, attaching to epithelial cells of the respiratory tract where they establish persistent colonization. Mycoplasma gallisepticum is the best-characterized avian Mycoplasma species, known to cause significant respiratory disease in poultry and an emerging conjunctival disease in wild and pet finches. Mycoplasma synoviae, while primarily causing synovitis, also produces respiratory disease. Other Mycoplasma species including Mycoplasma iowae and various uncharacterized species have been identified in pet birds with respiratory disease. The specific Mycoplasma species involved influences the clinical presentation and host range affected.

Transmission of Mycoplasma occurs through several routes that facilitate spread within and between bird populations. Direct contact with infected birds allows transmission through respiratory secretions exchanged during close interaction. Aerosol transmission occurs when infected birds cough or sneeze, creating droplets containing organisms that can be inhaled by nearby susceptible birds. Contaminated fomites including shared dishes, perches, and handling equipment can serve as transmission sources. Vertical transmission from infected hens to eggs allows perpetuation of infection across generations. Breeding facilities with infected birds can unknowingly distribute infection through sales of apparently healthy but infected offspring. The ability of carrier birds to transmit infection while appearing healthy complicates control efforts.

Risk factors for mycoplasma respiratory infection relate to exposure opportunities and factors affecting host resistance. Birds in high-density housing situations face increased exposure to infected individuals and their secretions. Pet store environments, breeding facilities, and rescue situations where birds from multiple sources mix present elevated risk. Newly acquired birds may carry Mycoplasma from their source, introducing infection to established collections. Stress from transport, environmental changes, breeding, or concurrent illness can trigger clinical disease in carrier birds and increase susceptibility in exposed birds. Poor ventilation concentrates respiratory pathogens and facilitates transmission. Young birds may be more susceptible to clinical disease, though infection occurs across age groups.

Certain species appear more commonly affected by mycoplasma respiratory infection, reflecting either true increased susceptibility or increased exposure and testing. House finches and their relatives are notably affected by Mycoplasma gallisepticum conjunctivitis, which has spread as an epidemic through wild finch populations. Cockatiels are frequently diagnosed with Mycoplasma respiratory infections, often presenting with sinusitis. Budgerigars and other small parakeets commonly develop mycoplasma infections. Poultry species including chickens, turkeys, and game birds are heavily impacted by several Mycoplasma species. The range of susceptible species continues to expand as diagnostic testing improves and awareness increases.

The mechanism by which Mycoplasma causes respiratory disease involves adherence to and damage of respiratory epithelium. Mycoplasma organisms attach to the surface of epithelial cells using specialized attachment proteins. Once attached, they compete with host cells for nutrients and can cause direct damage to the epithelium. The immune response to infection causes inflammation that contributes to clinical signs. Mycoplasma can modulate host immune responses in ways that allow persistent infection despite antibody production. The organisms can survive within host cells in some cases, contributing to persistence. Chronic infection leads to epithelial changes and increased susceptibility to secondary bacterial pathogens that worsen disease.

Early warning signs of mycoplasma respiratory infection may be subtle and easily overlooked in their initial stages. Occasional sneezing that occurs more frequently than expected may be an early indicator. Mild nasal discharge that appears clear and watery initially may be noted. Slight swelling around the eyes or nares may be visible in some birds early in infection. Activity levels may decrease slightly before more obvious signs develop. Appetite may decline marginally. Weight loss may begin subtly. The bird may seem slightly less vocal or energetic than usual. These early signs develop gradually and may be attributed to minor illness or environmental factors before the chronic nature of mycoplasma infection becomes apparent.

Common symptoms of established mycoplasma respiratory infection include prominent nasal discharge that may be clear, mucoid, or in complicated cases, purulent. Sneezing becomes frequent and noticeable. Sinus swelling is characteristic, particularly affecting the infraorbital sinuses adjacent to and below the eyes, creating visible facial swelling. Respiratory sounds such as wheezing, clicking, or rattling may be audible. Conjunctivitis with redness, swelling, and discharge from the eyes is common, particularly in finches with Mycoplasma gallisepticum. Breathing may become labored in more severe cases, though mycoplasma infection typically causes less severe respiratory distress than some other respiratory pathogens.

Behavioral changes in birds with mycoplasma respiratory infection reflect both the respiratory compromise and general malaise. Affected birds show decreased activity levels with reduced interest in play and exploration. Appetite typically decreases, contributing to weight loss over time. Vocalization may decrease in frequency and quality. Social birds may withdraw from flock mates or interact less with caregivers. Sleeping patterns may change with increased daytime rest. Preening activity often decreases, leading to unkempt feather appearance. The behavioral changes develop gradually, paralleling the chronic progression of the disease. Affected birds may appear sick but continue to function at reduced levels for extended periods.

Physical signs visible on examination include the characteristic facial swelling from infraorbital sinusitis. The feathers around the eyes and nares may be matted with discharge. Nasal passages may appear blocked or narrowed on examination. Conjunctival redness and discharge may be visible. Body condition may decline with prominent keel bone reflecting weight loss. Droppings may show reduced fecal component from decreased food intake. In more severely affected birds, respiratory effort may be increased. The bird may feel lighter than expected. Overall demeanor is typically subdued but not as severely depressed as in some acute respiratory infections.

Symptom progression in mycoplasma respiratory infection typically follows a chronic waxing and waning course rather than acute deterioration. Signs may improve partially then worsen again over weeks to months. Stress events can trigger flare-ups in chronically infected birds. Secondary bacterial infections can cause acute worsening. Without treatment, chronic infection persists with ongoing low-grade to moderate signs. The sinuses may become chronically thickened and prone to recurrent infection. Weight loss may continue gradually. Over time, chronic respiratory compromise can lead to significant debilitation. However, the gradual nature of decline means birds often present with advanced chronic disease rather than acute illness.

Emergency symptoms in mycoplasma respiratory infection are less common than with some other respiratory diseases but can occur. Severe respiratory distress with open-mouth breathing indicates serious compromise requiring immediate attention. Complete obstruction of nasal passages causing dyspnea requires urgent care. Severe secondary bacterial infection can cause acute deterioration. Profound weakness, collapse, or complete food refusal necessitate emergency veterinary evaluation. While uncomplicated mycoplasma infection rarely causes acute life-threatening illness, chronically debilitated birds are vulnerable to sudden decompensation from secondary problems or concurrent disease.

The initial examination for suspected mycoplasma respiratory infection includes careful history-taking focused on the duration and progression of respiratory signs. The avian veterinarian asks about exposure to other birds, recent acquisitions, and any illness in contact birds. The characteristic chronic course with sinus involvement suggests mycoplasma as a differential diagnosis. Physical examination notes facial swelling, nasal discharge, conjunctival involvement, and overall condition. Auscultation may reveal respiratory sounds. The sinuses may be palpated to assess extent of involvement. Body condition and weight are recorded. The examination helps differentiate mycoplasma infection from other causes of chronic respiratory disease.

Diagnostic tests for mycoplasma respiratory infection include samples for organism detection and assessment of disease extent. Choanal and conjunctival swabs are collected for testing. Nasal or sinus aspirates may be obtained if fluid is accessible. Blood work typically shows changes consistent with chronic infection, though findings may be relatively mild compared to some bacterial infections. Radiographs can reveal changes consistent with sinusitis and may show lower respiratory involvement in advanced cases. Cytology of respiratory samples may show inflammatory cells and sometimes reveal organisms, though Mycoplasma are very small and difficult to visualize on routine stains.

Specific testing for Mycoplasma species includes culture, PCR, and serology. Mycoplasma culture requires specialized media and techniques, and these fastidious organisms can be difficult to grow. Culture results may take weeks. PCR testing provides faster results and can detect Mycoplasma DNA in respiratory samples with good sensitivity. PCR can often identify the specific Mycoplasma species present. Serology measuring antibodies to Mycoplasma can indicate exposure, though interpretation may be complicated by prior infection, vaccination in some species, or cross-reactions. Combining testing modalities increases diagnostic accuracy.

Differential diagnosis for mycoplasma respiratory infection includes other causes of chronic respiratory disease, particularly those involving the sinuses. Chlamydiosis causes respiratory signs and should be ruled out, particularly given its zoonotic implications. Aspergillosis can cause chronic respiratory disease though it less commonly causes the characteristic sinus swelling. Bacterial sinusitis from other organisms may appear similar. Vitamin A deficiency causes respiratory epithelial changes and increased susceptibility to infection. Upper respiratory infections from various causes may have overlapping presentations. The chronic course and characteristic sinus involvement point toward mycoplasma, but specific testing confirms the diagnosis.

Confirmation of mycoplasma respiratory infection diagnosis relies on positive specific testing combined with compatible clinical signs. A positive PCR result from a bird with chronic respiratory disease and sinusitis is considered diagnostic. Positive culture definitively confirms viable organism presence. Serology may support the diagnosis in context. The veterinarian discusses findings with the owner, explains the chronic nature of mycoplasma infection, outlines treatment options, and addresses prognosis. If the bird is part of a collection, implications for other birds and recommendations for testing and management are discussed.

Emergency and immediate treatment for mycoplasma respiratory infection is rarely required, as the disease typically presents as chronic illness rather than acute crisis. However, birds with severe secondary bacterial infection or respiratory compromise may need stabilization. Supportive care including heat, hydration, and nutritional support addresses debilitation. Oxygen supplementation assists birds in respiratory distress. Anti-inflammatory medications may provide symptomatic relief. Once the bird is stable, specific antimicrobial therapy is initiated. Emergency situations in mycoplasma infection usually result from complications rather than the primary infection.

Medical management of mycoplasma respiratory infection centers on antibiotic therapy with agents effective against these cell wall-lacking organisms. Doxycycline is commonly used and is effective against most avian Mycoplasma species. Fluoroquinolones such as enrofloxacin provide an alternative with good respiratory tissue penetration. Macrolide antibiotics including azithromycin and tylosin are also effective options. Because Mycoplasma lack cell walls, beta-lactam antibiotics like penicillins and cephalosporins are ineffective. Treatment duration must be extended, typically three to six weeks minimum, as shorter courses frequently result in relapse. Complete elimination of Mycoplasma may not be achieved, and some birds remain carriers after treatment.

Sinus management may be necessary in birds with significant sinusitis. Sinus flushing with saline or antibiotic-containing solutions can help clear accumulated debris and deliver medication directly to affected tissue. This procedure is typically performed under sedation or anesthesia by experienced practitioners. Repeated flushes may be needed in severe cases. In rare instances, surgical intervention for chronic sinusitis may be considered if conservative management fails. Opening thickened sinus cavities to improve drainage has been described. However, most cases respond to medical management with antibiotics and supportive care.

Supportive care complements antibiotic therapy and addresses the effects of chronic illness. Nutritional support ensures adequate caloric intake for birds with reduced appetite. Vitamin A supplementation may be indicated if deficiency has contributed to respiratory epithelial vulnerability. Nebulization with saline helps moisten and loosen respiratory secretions. Environmental optimization including appropriate temperature, humidity, and excellent air quality supports recovery. Stress reduction through minimized handling and a calm environment helps immune function. Secondary bacterial infections are treated with appropriate additional antibiotics based on culture and sensitivity.

Alternative and complementary treatments may be considered alongside standard therapy. Probiotics may support gastrointestinal health during extended antibiotic therapy. Immune-supporting supplements are used by some practitioners. Steam or humidification helps loosen respiratory secretions. Herbal preparations with antimicrobial properties are sometimes employed as adjuncts. Environmental treatments including air quality optimization and stress reduction support medical therapy. These approaches should complement rather than replace appropriate antibiotic treatment.

Treatment decision factors in mycoplasma respiratory infection include the severity of disease, the presence of secondary infections, and the bird's role in a collection or breeding program. Mild cases may respond to standard antibiotic courses, while severe or chronic cases require extended or repeated treatment. Carrier birds that appear healthy but shed organisms present challenges for collections. The cost of extended treatment and monitoring should be discussed. In breeding situations, decisions about whether to treat versus remove infected birds depend on the value of individuals and feasibility of elimination. Expected outcomes include improvement in clinical signs, though complete elimination of organisms may not be achieved.

The recovery timeline for mycoplasma respiratory infection typically shows initial clinical improvement within one to two weeks of starting appropriate antibiotic therapy. Nasal discharge and sneezing usually decrease as treatment progresses. Sinus swelling may take longer to resolve, with improvement noted over several weeks. Appetite and activity levels often improve as the bird feels better. However, the full treatment course must be completed regardless of clinical improvement to maximize the chance of organism suppression. Complete recovery may take four to eight weeks or longer in severe cases. Some residual sinus changes may persist even after clinical resolution.

Post-treatment care for mycoplasma respiratory infection involves monitoring for relapse, which is common with this persistent pathogen. Birds should be observed for return of respiratory signs following treatment completion. Follow-up veterinary examination confirms clinical resolution. Repeat testing may be performed to assess whether organisms remain detectable. Environmental management to reduce reexposure and stress helps prevent recurrence. Nutritional optimization supports ongoing respiratory health. Any return of symptoms should prompt veterinary evaluation and possible retreatment. Long-term monitoring is important given the tendency for chronic carriage and recurrence.

Prognosis factors in mycoplasma respiratory infection include the severity and duration of disease before treatment, the specific Mycoplasma species involved, and response to therapy. Birds with mild disease of short duration generally have excellent prognosis for clinical recovery. Chronic cases with extensive sinus changes may have persistent low-grade signs despite treatment. Secondary bacterial complications can worsen prognosis if not adequately addressed. Complete elimination of Mycoplasma may not be achieved, with carrier states persisting after clinical recovery. Owner compliance with extended treatment improves outcomes.

The long-term outlook for birds recovered from mycoplasma respiratory infection is generally good for quality of life, though chronic carriage is common. Many birds return to normal activity and behavior after treatment. However, they may remain susceptible to flare-ups during stress. Carrier birds may transmit infection to others, which is important in collection and breeding settings. Regular monitoring allows early intervention if signs recur. Preventing stress and maintaining excellent husbandry supports long-term respiratory health. Some birds require periodic retreatment for recurrent clinical episodes. Overall, mycoplasma infection is manageable even if not completely curable in many cases.

Environmental prevention of mycoplasma respiratory infection focuses on reducing transmission opportunities and maintaining conditions that support respiratory health. Good ventilation provides fresh air while avoiding drafts that stress birds. Air quality should be excellent with low dust and ammonia levels. Overcrowding should be avoided to reduce transmission opportunities and stress. Regular cleaning of cages and equipment reduces environmental contamination. Shared food and water sources can facilitate transmission and should be cleaned frequently. Environmental temperature and humidity should be appropriate for the species. These measures reduce both transmission risk and susceptibility to infection.

Quarantine and testing protocols are essential for preventing mycoplasma introduction to collections. New birds should be quarantined for a minimum of thirty days, with longer periods providing greater safety. Testing for Mycoplasma during quarantine identifies infected birds before they can transmit to others. PCR testing of choanal and conjunctival samples provides good sensitivity for detection. Birds from high-risk sources such as large breeding operations or pet stores warrant particular attention. Birds showing any respiratory signs during quarantine should be tested and treated before introduction. Strict separation between quarantine and resident birds prevents transmission during the isolation period.

Closed flock management helps prevent mycoplasma introduction in breeding programs. Once a collection is established as Mycoplasma-free through testing, new birds should not be added or should only be added after rigorous testing and quarantine. Breeding within a closed, tested population prevents introduction of infection. Birds leaving for shows or other events should be housed separately upon return. Visitors and equipment from other bird facilities should be managed to prevent pathogen introduction. These measures are particularly important for valuable breeding stock and species sensitive to respiratory infection.

Health maintenance practices support disease resistance. Regular avian veterinary examinations allow early detection of respiratory problems. Optimal nutrition including adequate vitamin A supports respiratory epithelium health. Minimizing stress through appropriate housing, social interaction, and environmental enrichment promotes immune function. Treating concurrent health problems prevents immunocompromise that increases susceptibility. Maintaining appropriate flock density reduces transmission pressure and stress. These practices create an environment less conducive to mycoplasma infection establishment.

Early intervention when mycoplasma infection is suspected limits disease spread and severity. Any bird with chronic respiratory signs, particularly sinus involvement, should be evaluated promptly. Testing should be pursued when mycoplasma infection is suspected. Affected birds should be isolated from healthy birds pending diagnosis. Prompt treatment of confirmed cases reduces organism shedding and transmission risk. Contact birds may warrant testing. Collection-level decisions about treatment, testing, and potentially culling infected birds should be made in consultation with an avian veterinarian experienced in flock health management.

Daily management of a bird with mycoplasma respiratory infection requires consistent medication administration over extended periods. Antibiotics must be given exactly as prescribed, with careful attention to dosing, timing, and any dietary modifications needed for drug absorption. Doxycycline absorption is reduced by calcium, so calcium-rich foods and supplements should be limited during treatment. Weight should be monitored to track condition and guide dosing. Respiratory status should be assessed daily, noting nasal discharge, sneezing frequency, and breathing effort. Food and water intake should be recorded. The bird's environment should be optimized for respiratory health with clean air and appropriate temperature and humidity.

Home environment modifications support recovery and minimize respiratory irritation. The cage should be positioned in an area with good air quality, away from kitchens, drafts, and heating or cooling vents. Air filtration can improve air quality in the bird's room. Humidity should be moderate, as both very dry and very humid conditions can stress the respiratory system. Substrate should be dust-free and changed regularly to maintain cleanliness. The cage should be easy to clean to maintain excellent hygiene. Perches should be comfortable and at appropriate heights for the bird's energy level.

Quality of life considerations remain important during treatment for chronic respiratory disease. While rest is important during acute illness, birds that are recovering can gradually return to normal activities. Mental stimulation through appropriate toys and interaction supports psychological well-being. Social contact with trusted caregivers provides important support during extended treatment periods. Favorite foods can encourage appetite in birds with reduced interest in eating. The bird's comfort and enjoyment of life should be regularly assessed. Treatment goals should include quality of life, not just disease parameters.

Monitoring during treatment includes tracking both clinical response and compliance. Owners should observe respiratory signs, appetite, and activity level daily. Weight should be recorded regularly. Any worsening or failure to improve should prompt veterinary consultation. Follow-up veterinary examinations allow professional assessment of response and adjustment of treatment as needed. After treatment completion, continued monitoring for relapse is important given the tendency for mycoplasma infection to recur. Signs to watch for include return of nasal discharge, sneezing, sinus swelling, or respiratory sounds. Early intervention for recurrence improves outcomes.

Caregiver support resources help owners manage extended treatment for mycoplasma respiratory infection. The treating veterinary team provides medical guidance throughout treatment. Written medication instructions and schedules help ensure compliance. Information about the chronic nature of mycoplasma infection helps owners set appropriate expectations. Connecting with other bird owners who have managed similar conditions can provide practical tips and emotional support. Financial planning for potentially extended or repeated treatment courses prevents treatment discontinuation. Celebrating improvements and milestones helps maintain caregiver engagement during lengthy treatment periods.

High-risk species for mycoplasma respiratory infection include those with documented high prevalence and susceptibility. House finches and related species have experienced epidemic spread of Mycoplasma gallisepticum conjunctivitis in wild populations, and captive finches are similarly susceptible. Goldfinches, purple finches, and other cardueline finches can be affected. Cockatiels are commonly diagnosed with mycoplasma respiratory infections in clinical practice, often presenting with characteristic sinusitis. Budgerigars and other small parakeets frequently develop mycoplasma infections. Poultry species including chickens and turkeys are heavily impacted by Mycoplasma gallisepticum and Mycoplasma synoviae. Game birds including pheasants and quail are susceptible. The range of affected species continues to expand as diagnostic awareness increases.

Moderate risk species include other pet birds that may develop mycoplasma infections under certain conditions. Larger psittacines including Amazon parrots, African Grey Parrots, and cockatoos can develop mycoplasma infections, though they may be less commonly diagnosed than smaller species. Canaries and other finches beyond the house finch group may be affected. Lovebirds and parrotlets show susceptibility. Doves and pigeons can harbor Mycoplasma species. The risk increases in any species housed in high-density situations, exposed to birds from multiple sources, or experiencing stress that compromises immunity.

Screening recommendations for mycoplasma infection focus on high-risk situations and species. New finches should be tested during quarantine given the high prevalence in this group. Cockatiels and budgerigars from pet stores or breeding facilities warrant testing. Any bird with chronic respiratory signs or sinusitis should be tested regardless of species. Breeding birds should be tested to prevent vertical and horizontal transmission. Pre-purchase testing for valuable birds provides protection. Collection screening may be appropriate when mycoplasma infection is suspected based on clinical patterns. PCR testing of appropriate samples provides reliable detection. Testing protocols should account for potential intermittent shedding by including repeat testing in high-risk situations.

Commonly co-occurring conditions with mycoplasma respiratory infection include secondary bacterial infections that frequently complicate primary mycoplasma disease. When Mycoplasma damages the respiratory epithelium, opportunistic bacteria can establish secondary infection, worsening clinical signs and complicating treatment. Vitamin A deficiency commonly accompanies or predisposes to mycoplasma infection, as deficiency causes squamous metaplasia of respiratory epithelium that increases infection susceptibility. Other concurrent respiratory pathogens including Chlamydia may be present. Stress-related conditions that trigger clinical disease in carrier birds may themselves require management. Immunosuppressive conditions from other causes increase susceptibility to mycoplasma infection.

Conditions with similar symptoms that must be differentiated from mycoplasma respiratory infection include other causes of chronic respiratory disease. Chlamydiosis causes respiratory signs with conjunctivitis and must be ruled out given its zoonotic potential. Aspergillosis causes chronic respiratory disease though the presentation typically differs from mycoplasma. Bacterial sinusitis from other organisms may appear similar. Vitamin A deficiency causes respiratory changes and predisposes to infection. Upper respiratory infections from various causes may have overlapping presentations initially. The chronic course with sinus involvement is relatively characteristic of mycoplasma, but specific testing differentiates causes.

Potential complications of mycoplasma respiratory infection include chronic sinusitis with permanent sinus changes that predispose to recurrent infection. Secondary bacterial infections can become established and cause acute worsening. Chronic respiratory compromise can lead to progressive debilitation. In breeding situations, vertical transmission perpetuates infection across generations. Spread to other birds in a collection can occur from carrier birds that appear healthy. Treatment failure and development of antibiotic resistance can occur with incomplete treatment courses. While mycoplasma infection is rarely immediately life-threatening, chronic disease and its complications can significantly impact quality of life and longevity.